We are seeking volunteers for a survey to learn what may encourage and discourage cancer patients to be in cancer research studies. We'd like to hear from you if you are: -18 years+ -Have been diagnosed with cancer or the caregiver of someone diagnosed with cancer. -Spend time in Bertie, Hertford, Robeson or Scotland County, NC or a neighboring county. Participation includes 1 survey (about 10 minutes long) that can be done with your mobile device, computer, or by phone with the researcher. Compensation: 1 in 10 participants will receive a $25 Visa gift card.

This study enrolling people who recurrent (has come back) or refractory (did not respond to treatment) classical Hodgkin lymphoma or CD30-positive peripheral T-cell lymphoma (PTCL). The purpose of this study is to learn about the effectiveness and safety of a new study drug called AFM13 when used in combination with a new cell therapy called AB-101. The study will also look at how the body processes this combination of drugs (called "pharmacokinetics").

We would like to learn about how people who apply for healthcare financial assistance experience the application process, including things that make the application process work well or that were challenging. At this time we are not able to offer interviews to people who applied to UNC or Duke, we are interested in hearing from people who applied to other programs (such as Atrium, Novant, Wake, Vidant, ECU, Cape Fear Health Net, Physicians Reach Out, or Project Access).

We are doing this study to test a behavioral lifestyle program designed specifically for adolescent and young adult cancer survivors. Study participants will use a smartphone app and Fitbit activity tracker to help them develop healthier habits.

Are you over 60 and were recently diagnosed with mantle cell lymphoma? You may be able to participate in a research study to determine whether patients who reach complete disease remission after treatment with rituximab and zanubrutinib, will remain longer in remission with or without continuous zanubrutinib treatment.

Have you been diagnosed with B-cell post-transplant lymphoproliferative disorder (PTLD) after an organ transplant? Have you not yet received any type of treatment for this condition? Then you may be eligible for a study to look at the safety and effectiveness of tafasitamab and rituximab combination treatment for PTLD.

Have you been recently diagnosed with follicular lymphoma (a type of non-Hodgkin lymphoma)? You may be able to take part in a research study to learn more about the safety and tolerability of an experimental drug called odronextamab.

Have you been diagnosed with cancer or a benign disease that is being evaluated for cancer for which you may receive treatment? If so, you may be able to take part in a research study that collects biospecimens (e.g. blood, saliva, tissue, etc) and health information to better understand how cancers develop and affect the body,]. If so, you may be able to take part in a research study that aims to identify non-invasive biomarkers for cervical cancer screening and monitoring following treatment of abnormal areas on the cervix caused by HPV.

This is a prospective study that will look for the kinetics of circulating tumor DNA (ctDNA) in patients with hematologic and pediatric cancer before and after undergoing standard of care treatment regimens where radiation therapy is a treatment.

Have you been diagnosed with CD30 negative peripheral T-cell lymphoma? If so, you may be able to take part in a research study that will look at the safety of adding the new study drug duvelisib, or the new study drug CC-486, to the standard chemotherapy treatment for your disease. Please contact us with questions about eligibility, or if you wish to know more.